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ABSTRACT 
Epiretinal membrane (ERM) is a pathologic tissue that develops at the vitreoretinal interface. ERM is responsible for 
pathological changes of vision with varying degrees of clinical significance. It is either idiopathic or secondary to a wide 
variety of diseases such as proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR). A great 
variation in the prevalence of idiopathic ERM among different ethnic groups proposed that genetic and lifestyle factors 
may play a role in ERM occurrence. Histopathological studies demonstrate that various cell types including retinal 
pigment epithelium (RPE) cells, fibrocytes, fibrous astrocytes, myofibroblast-like cells, glial cells, endothelial cells (ECs) 
and macrophages, as well as trophic and transcription factors, including transforming growth factor (TGF), vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) etc., are directly or indirectly involved in the 
pathogenesis of  idiopathic or secondary ERMs. These processes are driven (on the last count) by more than 50 genes, 
such as Tumor Necrosis Factor (TNF), CCL2 (chemokine (C-C motif) ligand )), Metastasis Associated Lung Adenocarcinoma 
Transcript 1  ) MALAT1(, transforming growth factor (TGF)-β1, TGF-β2, Interleukin-6 (IL-6), IL-10, VEGF and glial fibrillary 
acidic protein (GFAP), some of which have been studied more intensely than others. The present paper tried to 
summarize, highlight and cross-correlate the major findings made in the last decade on the function of these genes and 
their association with different types of cells, genes and gene expression products in the ERM formation. 
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INTRODUCTION
Epiretinal membrane (ERM) is a pathologic layer, located at 
the vitreoretinal interface, which grows on the inner surface 
of the retina [1, 2]. It is mainly localized on the central retina 
or the surface of macula [3]. ERM was first described by 
Iwanoff in 1865 [4-8]. It has been designated by many 
names, such as primary retinal folds, wrinkling of the inner 
retinal surface, silent central retinal vein obstruction, 
preretinal macular fibrosis (PMF) or gliosis, or macular 
pucker and cellophane maculopathy [3].  
ERMs can be either idiopathic or secondary [9-13]. In 
idiopathic or primary ERM, cell proliferation appears 
following posterior vitreous detachment (PVD) [9], in up to 
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95% of the cases [14] and a break in Internal Limiting 
Membrane (ILM). Furthermore, two types of idiopathic ERM 
have been introduced. Type I refers to cases where vitreous 
collagens intervene between ILM and ERM, while the 
second type describes those where cell proliferation takes 
place directly on the ILM surface with only a sparse or even 
no collagen containing layer forming between them [15].  
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Secondary ERMs are the result of an already existing ocular 
pathology, including vitreoretinal vascular disorders. 
Common causes include PVR, PDR, hypertensive 
retinopathy as well as diseases like intraocular inflammation 
(e.g., uveitis), occlusion of a central or branch retinal vein, 
retinal detachment (RD) and ocular trauma [9-12]. 
Secondary ERMs are also attributed to retinal tears, retinal 
photocoagulation, cryotherapy, retinal vasculitis, vitreal 
hemorrhages and retinal surgical procedures [9, 10, 16]. 
ERMs therefore, can be vascularized (e.g., in eyes with 
proliferative retinopathies), or avascular [10]. However, 
secondary ERMs are less aggressive and seldom cause 
traction RD as do primary ERMs [17].   
Structurally, ERM includes an inner and an outer 
extracellular matrix (ECM) layer. The first one includes one 
or multiple cell layers while the second one contains 
randomly oriented extracellular fibrils, in most cases [15, 18, 
19]. The epiretinal cells, of either retinal or extraretinal 
origin may be glial cells (Müller cells and astrocytes), RPE, 
fibrocytes, myofibroblasts, fibroastrocytes, laminocytes, 
hyalocytes, macrophages or fibroblasts [6, 12, 16, 18]. In its 
outer layer, the ECM includes extracellular fibrils, fragments 
of ILM, residual native vitreous fibrils in cases like 
vitreoschisis or partial PVD [19]. It also contains proteins, 
e.g., fibronectin (FN), vitronectin (VTN) or collagen [6, 16, 
18].   
Nonangiogenic fibroglial tissue characterizes idiopathic 
ERMs, in contrast to PDR ERMs which are mainly 
characterized by neovascularization [20, 21]. ERM is the 
most severe stage of PDR, because of retinal traction or 
tractional RD secondary to ERM contraction [22]. However, 
both idiopathic and secondary ERM formation have poorly 
understood molecular mechanisms [20], although, glial cell 
proliferation which follows PDR [20, 23] is suspected to 
have a vital role in ERM formation.  
Fibrocellular proliferation of ILM and cellular contraction are 
also ERM features. PVD can injure the ILM, allowing 
movement of glial cells to the retinal surface and favorable 
conditions for fibrocellular proliferation, between the 
vitreous and the retina. This might be provided by an 
incomplete PVD as well [4-7].  
The present paper tried to summarize (Tables 1, 6), highlight 
and cross-correlate (Tables 2, 3, 4, 5) the major findings 
made in the last decade on the function of these genes and 
their association with different types of cells, genes and 
gene expression products involved in ERM pathogenesis. 
Based on the review literature, this article focuses and 
attempts to summarize, highlight and cross-correlate the 
major findings about the role of cells, genes and gene 
expression products implicated in ERM formation, idiopathic 
and secondary. 
METHOD 
This was a literature research on PubMed and the Scholar 
databases for articles related to the pathogenesis of ERM, 
idiopathic or secondary. “Epiretinal membrane”, “genes”, 
“genetic associations”, “proteins”, “growth factors” and 
“pathogenesis” are the keyword combinations used. The 
research represents a critical appraisal focused on articles 
dated from January 2008 until December 2019. A total of 60 
articles were identified, and the analysis of their references 
revealed an additional 78 articles related to ERM 
pathogenesis, which were also reviewed.  
General aspects of ERM pathogenesis 
Migration of retinal-tissue-derived glial cells from the optic 
disc together with microdefects in the ILM (retinal pits or 
holes), which occur during PVD and move towards the 
surface of the retina may contribute to the pathogenesis of 
ERM [3, 15, 24, 25]. Other theories suggest that as an 
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incomplete PVD allows the membrane proliferation 
between the vitreous and the retina, the pathogenesis of 
ERM is associated with the growth and fibrous metaplasia of 
the vitreous cells [9, 14, 16]. The retinal break provides 
suitable conditions for the migration of the RPE cells to the 
vitreous cavity and migration to the retinal surface, forming 
the ERM in the case of rhegmatogenous RD [24, 26]. Thus, 
PVD seems to be a crucial pathogenic factor in idiopathic 
ERM formation as it is encountered in 70% of patients at the 
earlier stages of disease [19]. Modifications of the ERM 
macromolecules may increase membrane stiffness and 
provide suitable conditions for the fibrotic process. Glial 
cells, fibroblasts, hyalocytes, along with cytokines and 
growth factors present in the vitreous fluid (VF) may 
contribute to ERM pathogenesis. Although there is a debate 
about which types of cells are responsible for idiopathic 
ERMs and the pathogenetic ways by which they migrate to 
the retinal surface [15]. 
Clinical Signs 
ERMs impact negatively the quality of life leading to 
significant visual impairment [27, 28]. They are 
characterized by several pathological changes occurring in 
the vitreoretinal junction differently expressed with various 
clinical signs [24, 25, 29, 30]. Clinically, ERMs appear on 
ophthalmoscopic examination as a translucent, transparent, 
or pigmented membrane, or like a glistening light reflection 
when the ERM is thin [3, 11, 19].  
Although, the early form of thin and translucent ERM is 
usually non-symptomatic or may provoke minor changes in 
visual acuity, which is seldom below 20/200, the more 
severe forms characterized by a semi translucent, thick, and 
contractile membrane can cause significant loss of visual 
acuity and a number of visual symptoms [3, 11, 19, 31, 32]. 
ERMs may be peripheral or macular. Macular ERMs are 
more visually disturbing [6, 33, 34]. They may involve 
macular and/or perimacular regions causing a reduction in 
visual acuity, micropsia, metamorphopsia, retinal wrinkling, 
distortion, blurred vision and occasionally monocular 
diplopia [12, 14, 19, 31, 35, 36]. However, absolute 
scotomas are rare [3]. ERMs may also cause vitreoretinal 
tractions or even tractional RD [12] as they often exert 
traction on the underlying retina, reducing visual acuity 
when they result in tractional detachment of the macula [3, 
10]. Symptoms may differ individually depending on the 
duration and severity of disease [12].  
Epidemiology and Risk Factors 
Despite extensive observations about ERM, its pathogenesis 
and pathophysiology are still poorly understood [9, 37].   
The most consistently identified risk factors for ERM are age 
and PVD [13, 19, 38], with PVD encountered in 70% of 
patients at the earlier stages of disease [19]. Occasionally, 
ERMs develop in children and young adults [3], but 
prevalence of ERM increases with age with most ERMs 
occurring in individuals older than 50 years [3, 14, 28, 38]. It 
is estimated that the incidence approaches 20% of the total 
population by the age of 70 years [24, 25], while the 
prevalence of macular ERMs is estimated to be 2% when 
patients are younger than 60 years, 12% in patients over 70 
years [6, 33] and 22.5% in those aged 80 years or more [19, 
31, 39]. Other population studies indicate that overall ERM 
prevalence is 7% to 11.8%, while the 5-year incidence is 
5.3% [1, 6, 7, 33, 37, 40, 41].  
ERM prevalence does not differ significantly between men 
and women [19, 31, 39]. On the other hand, it shows 
substantial racial and ethnic variation [28]. Epidemiologic 
studies, among different ethnic groups, report great 
discrepancies in the prevalence of idiopathic ERM, ranging 
from 1.02% to 28.9%. ERM is more prevalent in the United 
States (USA) and Australia compared to Asian countries, like 
China, Japan and Singapore, pointing to genetics and 
lifestyle [18, 19] as predisposing factors. Interestingly, these 
studies indicated no important differences of the 
prevalence of PMF, a severe form of idiopathic ERM, which 
should be treated with surgical intervention [19].  
There are almost 30 million people in the USA having ERM 
in at least one of their eyes. Moreover, the prevalence 
seems to be lower in Asia, markedly lower in China [11, 28] 
but higher in Asian Malays, compared with Caucasians [38], 
but it is similar between Japanese and Caucasians. Finally, 
the prevalence of ERM among those of Southern European 
origin appears to be twice that in those of Northern 
European origin, while a high prevalence is also reported for 
the U.S. Latinos [11, 28].  
The role of race and ethnicity in the prevalence of ERM has 
remained unclear [13, 14, 40]. However, they may relate to 
the different study methods used including sampling, 
photography etc., or the definition of ERM used, especially 
when the clinical signs are not already obvious [28]. Ethnic 
variations may also relate to different genetic 
predisposition, clinical factors, comorbidities (e.g., diabetes), 
previous cataract surgery and lifestyle factors (e.g., 
smoking). Exposure to unknown risk factors may also be 
involved. Nonetheless, as mentioned above, increasing age 
is the most common risk factor for any type of ERM [27].  
Increased prevalence of idiopathic ERM accompanies 
diabetes, hypercholesterolemia and vascular narrowing or 
occlusion. These associations suggest a strong role for 
metabolic factors [18, 19] in the development of ERM. In 
addition, cardiovascular risk factors appear to be associated, 
albeit inconsistently, with idiopathic ERMs [28]. However, 
this may be a manifestation of metabolic factors mentioned, 
given that they are causative factors of cardiovascular 
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disease. Finally, ERM could be associated with refractive 
errors, although relevant data are inconsistent; a number of 
studies indicated increased prevalence of idiopathic ERM in 
hypermetropic eyes, while others implicated myopic eyes 
[19].  
The Genetic and Proteomic Basis of ERM Pathogenesis 
Despite our incomplete knowledge of the pathogenesis of 
ERM [9], gene expression profiles carried under different 
conditions [17, 42] have identified several genes as crucial 
for ERM formation. Modern imaging in coordination with 
immunocytochemistry and proteomic techniques, improved 
our knowledge of the pathogenesis of idiopathic and 
secondary ERMs [15]. Apparently, not one or just a few 
growth factors influence the pathogenesis of ERMs [43]. 
Indeed, ERM appears to be mainly an avascular fibrocellular 
proliferation, given that a number of ECM proteins and cells 
like RPE and glial cells are components of ERM [9, 44].  
Cells Involved in ERM Pathogenesis 
ERMs are characterized by cellular migration and 
proliferation on the inner retinal surface [37], ECM 
formation and tissue contraction [29]. Histopathological 
studies indicate that RPE cells, glial cells, macrophages, ECs, 
fibrocytes, fibrous astrocytes and myofibroblast-like cells, as 
well as trophic and transcription factors contribute to ERM 
formation [1, 10, 24, 25, 29, 35, 45-51]. However, the 
stimuli causing epiretinal and intravitreal cellular 
proliferation and ERM formation are unknown. Imprecise 
morphologic criteria for cell-type identification, secretion of 
extracellular material and morphologic changes that occur 
in cells during proliferation and maturation of ERM 
contribute to the uncertainties about which cell types are 
involved in ERM pathogenesis [10].  
RPE cells is apparently the major cell type contributing to 
ERMs and intravitreal membranes in eyes with 
rhegmatogenous RD, which is complicated by massive 
periretinal proliferation [10]. RPE cells are hexagonal 
quiescent cells that neither proliferate nor migrate under 
physiological condition [52, 53]. However, there are several 
cell types (e.g., glial cells) which contribute to the fibrotic 
reaction in RD [54, 55], by way of protecting the retina 
through the formation of a scar-like thin layer [20, 23, 29, 
47, 48, 56, 57].  
Other cell types whose origin is not fully elucidated, 
especially in diabetic ERM, are fibroblasts [57, 58]. These 
cells synthesize the ECM, construct the structural 
framework of the membrane, are capable of producing 
collagen and, as a result, can cause tractional RD [57]. 
Myofibroblasts, possibly of hyalocyte, Müller cell, or RPE cell 
origin predominate in late idiopathic ERMs and have a 
crucial role in idiopathic ERM pathogenesis since they 
secrete contractile proteins, induce intracellular contraction 
and deposit collagen [14].  
Müller cells are other type of cells with central role in ERM 
contraction due to their ability to express a-smooth muscle 
actin (a-SMA), which is involved in membrane contraction 
and produce various collagens [1, 18, 20, 23, 59, 60]. 
Idiopathic ERM formation grows as Müller cells proliferate, 
migrate and transdifferentiate. Müller glial cells (MGCs) 
contribute to the formation of ERM, by acquiring migratory 
ability and exhibiting a fibroblast-like phenotype, stretching 
the retina and causing RD and vitreous hemorrhage. They 
are also involved in the formation of diabetic ERM, which is 
associated with reactive gliosis, fibrosis and migration [57, 
61]. Laminocytes are other cell types with fundamental 
involvement in the pathology of idiopathic ERMs. These are 
dispersed in reduced numbers in eyes containing a PVD 
[29]. Additionally, ERM formation and contraction are 
enhanced by the activation of hyalocytes that are placed on 
the cortical vitreous remnants. This process is enhanced by 
different growth factors contributing to the cellular 
proliferation and myofibroblast differentiation [10, 29] 
(Table 2). During the formation of idiopathic ERM, TGF-β 
is produced and activated by both hyalocytes and 
retinal Müller cells [18, 68-70]. 
Table 2. Some Cell Types in ERM Pathogenesis 
Cell Type Role 
Astrocytes Idiopathic ERM [47] 
Endothelial cells ERM formation [47, 62] 
Fibroblasts Idiopathic [63] and secondary (PDR) ERM [57, 58, 63] 
Fibrocytes ERM formation [29, 35, 47] 
Glial cells  Idiopathic and secondary (PVR) [64, 65] (PDR) [29, 50, 57, 61, 64] ERM  
Hyalocytes Idiopathic and secondary (PVR and PDR) ERM [9, 47, 66, 67] 
Laminocytes Idiopathic ERM [29] 
Macrophages Idiopathic ERM [10] and secondary (PVR) ERM [64] 
Müller cells Idiopathic [14, 18, 57, 61, 63, 69, 70] and secondary ERM [63] 
Myofibroblast-like cells Idiopathic [14, 47] and (PVR and PDR) secondary ERM [9, 47, 66, 67] 
RPE cells Idiopathic and (PVR and PDR) secondary ERM [9, 29, 47, 64, 66, 67] 
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TGF-β contributes to ERM contraction by upregulating 
the expression of a-SMA in the epiretinal cells. Non-
expressing a-SMA retinal Müller cells apparently 
produce collagens that form the ECM network in 
idiopathic ERM, while it is the retinal Müller cells that 
express a-SMA responsible for the membrane 
contraction [18]. The role of many other cell types, like 
macrophages, in the pathogenesis of idiopathic ERMs 
has yet to be determined [10]. 
Genes Involved in ERM Pathogenesis 
Several changes take place in gene expression during 
the onset as well as later in progress of various diseases 
[17, 71]. Genes with a crucial role in any particular 
disease can be identified through comparison of 
different gene expression profiles [17, 42]. Therefore, 
the analysis of gene expression can enhance the 
understanding of ERM formation.   
The expression of genes in idiopathic or secondary ERM 
has been extensively studied [47]. There are at least 52 
genes upregulated in either PVR or secondary ERMs. 
The expression of 29 genes is increased in secondary 
ERMs as the expression of 23 genes in PVR-ERMs. Four 
genes in particular, ZNF713, FN1, MALAT1 and PARP8, 
are highly upregulated in ERMs. Genes that contribute 
to proliferation and cell adhesion are highly expressed 
in PVR-ERMs, while in the rest of secondary ERMs, 
genes which are implicated in metabolism, ribosomes 
and signaling are slightly elevated [17]. Ten cell 
adhesion genes expressed in the PVR-ERMs are COL1A1, 
COL1A2, COL3A1, POSTN, THBS1, LGALS1, SPARC, FN1, 
TIMP3 and DCN. These findings are supported by 
morphological studies that enhance the positive 
correlation between the disease process with the 
amount of ECM in ERMs, especially in PVR-ERMs [17, 
72]. Genes like MALAT1, STAT3, CD320 and SERPINE1 
which are implicated in proliferation, are also 
upregulated in PVR-ERMs. In addition, several other 
genes and proteins, among them 60 genes not detected 
in PVR-ERM, may also be involved [17].    
Of genes mentioned above, MALAT1 is associated with 
ERM formation, with a crucial role in the progression of 
secondary, especially PVR, ERM. This gene is a large, 
non-coding RNA, highly conserved among mammals, 
which appears to be the most actively expressed PVR-
ERM gene. It is involved in the expression of genes 
associated with metastasis and motility at the level of 
transcription and/or post-transcription regulation [17, 
73]. As PVR-ERMs do not synthesize MALAT1, it is 
suggested that cell migration of PVR-ERMs on the retina 
may trigger the expression of MALAT1 in ERM [17].   
The expression of genes like RELA (v-rel avian 
reticuloendotheliosis viral oncogene homolog A), 
tenascin C (TNC), glial fibrillary acidic protein (GFAP) 
and other cytokine-encoding genes such as TGF-β2, IL-6, 
VEGFA and CXCL1 (chemokine C-X-C motif ligand 1) is 
intensified irrespective of sex, especially in idiopathic 
ERM eyes [47]. RELA is a component of the nuclear 
transcription factor kappa B (NF-κB). Hypoxia, infections 
by viruses and bacteria and proinflammatory cytokines 
such as IL1β and tumor necrosis factor alpha (TNF-a), 
apparently activate NF-κB [47, 74, 75]. It is suggested 
that a consequence of old age is the abundant 
representation of RELA in ECs and glial cells, which 
leads to upregulation of NF-κB, stimulation of the 
proliferation of glial cells [50, 62, 76] and IL-8, resulting 
in ERM formation [47, 62]. Numerous NF-κB target 
genes, among them proinflammatory cytokines, like 
IL1β and IL-6 and TNF-a (which are vital contributors to 
the formation of ERMs and the pathological process of 
DR) are potentially upregulated by activated glial cells 
[20, 66]. Indeed, patients with PDR ERMs have 
significantly higher NF-κB mRNA expression levels than 
those in idiopathic ERMs [50, 51]. 
Another gene that possibly plays an important role in 
ERM formation is the PPM1D gene. This gene encodes 
Wild-type p53-induced phosphatase 1 (Wip1), which 
has a key role in stress signaling [50, 77], inflammation, 
cell survival, cell cycle progression and proliferation [50, 
78]. In addition, there are several reports about the 
relation between ERMs of PDR and the expression of 
Wip1. Although Wip1 may be associated with ERM 
formation, little is known about this association [50].  
SP1 mRNA (specificity protein 1) is also highly 
represented in PDR-ERM. SP1 regulates expression of 
genes that encode angiogenesis-related factors and has a 
vital role in PDR angiogenesis [79]. SP1 regulates the 
expression of several genes, such as TGF-β, VEGF, 
fibrogenic cytokine and many matrix genes, while the SP1 
coded protein is co-localized mainly with VEGF. These 
cytokines have been detected in the VF and PDR-ERMs 
[79, 80] (Table 3).  
Genes associated with wound healing and angiogenesis 
along with the pro-inflammatory genes, TGF-β2, IL-6, 
RELA, GFAP, VEGFA, TNC and CXCL1 are slightly more 
expressed in eyes with idiopathic ERM [47], while there is 
a positive intraocular fibrosis and is upregulated in eyes 
with PVR and PDR ERM [9, 20, 29, 47, 57, 66, 67] and 
induce the transformation of RPE cells, hyalocytes and 
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Table 3. Genes, the Proteins They Encode and Their Role in ERM Pathogenesis 
GENES PROTEINS ENCODED ROLE 
CD320 (CD320 Molecule) CD320 antigen 
 
related to proliferation (PVR-ERM) [17] 
COL1A1  Collagen, type I, alpha 1 adhesion-related gene (PVR-ERM) [17] 
COL1A2 Collagen, type I, alpha 2 adhesion-related gene (PVR-ERM) [17] 
COL3A1  Collagen type III, alpha-1 adhesion-related gene (PVR-ERM) [17] 
CXCL1 (C-X-C Motif Chemokine Ligand 1) C-X-C Motif Chemokine Ligand 1 cytokine-encoding gene (idiopathic ERM) [47] 
DCN (DeCoRin) Decorin adhesion-related gene (PVR-ERM) [17] 
FN1 (FibroNectin-1) Fibronectin adhesion-related gene (PVR-ERMs and secondary 
ERM) [17] 
GFAP (Glial Fibrillary Acidic Protein) Glial fibrillary acidic protein pro-inflammatory genes (idiopathic ERM) [47, 81] 
IL-6 (InterLeukin-6) Interleukin-6 cytokine-encoding gene (idiopathic ERM) [47] 
LGALS1 (GALectin 1) Galectin-1 adhesion-related gene (PVR-ERM) [17] 
MALAT1 (RNA gene) (Metastasis Associated  
Lung Adenocarcinoma Transcript 1) 
non-coding RNA related to proliferation/ metastasis/ regulates 
processing pre-mRNAs in mammalian cells and cell 
motility (PVR-ERMs and secondary ERM) [17] 
PARP8 (Poly(ADP-Ribose) Polymerase 8) Poly [ADP-Ribose] Polymerase 8 (PVR-ERMs and secondary ERM) [17] 
POSTN (PeriOSTiN) Periostin adhesion-related gene (PVR-ERM) [17] 
PPM1D (Protein Phosphatase, Mg2+/Mn2+ 
Dependent 1D) 
Wild-type p53-induced phosphatase 1 (Wip1) active in stress signaling, inflammation, cell 
survival, cell cycle progression and proliferation 
(PDR-ERM) [50, 77] 
RELA (v-REL avian reticuloendotheliosis viral 
oncogene homolog A) 
nuclear factor NF-kappa-B p65 subunit regulation of cellular signal transmission, cell 
migration and apoptosis, and tumor growth and 
progression (idiopathic ERM) [47] 
SERPINE1 (SERPIN Family E Member 1) Serpin family E member 1 related to proliferation (PVR-ERM) [17] 
SP1 (Sp1 Transcription Factor) Sp1 transcription factor angiogenesis (PDR-ERM) [79] 
SPARC (Secreted Protein Acidic and Cysteine Rich) Osteonectin adhesion-related gene (PVR-ERM) [17] 
STAT3 (Signal Transducer and Activator of 
Transcription 3) 
Signal transducer and activator of 
transcription 3 
related to proliferation (PVR-ERM) [17] 
TGFβ2 (Transforming Growth Factor Beta 2) Transforming growth factor beta 2 cytokine-encoding gene (idiopathic ERM) [47] 
THBS1 (THromBoSpondin-1) Thrombospondin-1 adhesion-related gene (PVR-ERM) [17] 
TIMP3 (TIMP Metallopeptidase Inhibitor 3) Metalloproteinase inhibitor 3 adhesion-related gene (PVR-ERM) [17] 
TNC (Tenascin C) Tenascin C pro-inflammatory gene (idiopathic ERM) [47, 81] 
VEGFA (Vascular Endothelial Growth Factor A) Vascular endothelial growth factor A cytokine-encoding gene idiopathic ERM) [47] 
ZNF713 (Zinc Finger Protein 713) Zinc finger protein 713 transcriptional regulation (PVR-ERMs and 
secondary ERM)[17] 
Abbreviations: PVR: proliferative vitreoretinopathy; ERM: epiretinal membrane; COL1A1: collagen, type I, alpha 1; COL1A2: collagen, type I, alpha 2; 
COL3A1: collagen type III, alpha-1; CXCL1: C-X-C Motif Chemokine Ligand 1; DCN: decorin; FN1: fibronectin-1; GFAP: glial fibrillary acidic protein; IL-6: 
interleukin-6; LGALS1: galectin 1; MALAT1: metastasis associated lung adenocarcinoma transcript 1; PARP8: poly (ADP-Ribose) polymerase 8; POSTN: 
periostin; PPM1D: protein phosphatase, Mg2+/Mn2+ dependent 1D; Wip1: wild-type p53-induced phosphatase 1; PDR: proliferative diabetic 
retinopathy; RELA: v-REL avian reticuloendotheliosis viral oncogene homolog A; SERPINE1: SERPIN family E member 1; SP1: Sp1 transcription factor; 
SPARC: secreted protein acidic and cysteine rich; STAT3: signal transducer and activator of transcription 3; TGFβ2: transforming growth factor beta 2; 
THBS1: thrombospondin-1; TIMP3: TIMP metallopeptidase inhibitor 3; TNC: tenascin C; VEGFA: vascular endothelial growth factor A; ZNF713: zinc 
finger protein 713 
 
Glial cells like astrocytes or MGCs, which express 
GFAP, are associated with idiopathic ERM. Retinal glial 
cells produce VEGF [25, 47], whereas idiopathic ERMs 
are characterized by the association in gene 
expression levels between VEGFA and GFAP. TNC has a 
vital role in the sprouting of endothelial cells (ECs) 
cells during angiogenesis and also in several processes 
like inflammation and wound healing [47, 81]. 
Therefore, TGF-β2 and the factors, CXCL1, IL-6 and NF-
κB, are potential stimuli for GFAP positive cells that 
contribute to the process of fibrosis, while VEGFA and 
TNC may enhance idiopathic ERM formation [47]. 
Finally, the expression of several genes that encode 
cytokines in ERM eyes is enhanced, while it remains 
stable for other cytokine encoding genes. As 
mentioned above, genes like RELA, VEGFA, IL-6, TGF-β2, 
CXCL1, GFAP and TNC are significantly upregulated in the 
idiopathic ERM eyes, while ACTA1 and IL17A are not 
detected in idiopathic ERMs. In addition, the levels of 
CCL2 (chemokine (C-C motif) ligand 2), CCL5, CXCL10, 
TGF-β1, TNF, STAT3, RORC, TBX21, IFNG and POSTN does 
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Collagens and ERM 
Given the increased collagen deposition and 
membrane contraction, the ERM progression is a 
fibrotic process. Collagen plays a crucial role in ERM 
construction and collagen types I-VI are important 
components of idiopathic ERM [18, 82, 83]. It also has 
an essential role in proliferation and migration. 
Moreover, collagens bind to the cellular membrane 
receptors and have a significant role in matrix 
remodeling, fibrosis and cell signaling [44].    
On the basis of their collagenous fibrillar ECM, two 
major types of idiopathic ERM can be identified. One 
of them is characterized by high amounts of fibrils 
consisting of collagen type VI; the other by high 
amounts collagen types I and II [18, 83]. The role of 
collagen type VI seems to be vital because of its 
contribution to the proliferation, migration and 
fibroblasts to myofibroblasts transdifferentiation. 
Fibroblast transdifferentiation is a vital procedure for 
fibrosis, matrix remodeling and scar contraction in 
many fibrotic diseases including ERM [18, 44]. Type VI 
also contributes to a fine fibrillar network whose 
presence characterizes idiopathic ERM [18, 83-85].  
Collagen types I, III and IV are freshly produced during 
idiopathic ERM formation. They promote the fibrotic 
process and contribute to the formation of hard 
collagen scaffold, where the myofibroblast precursor 
cells, when anchored there, become more susceptible 
to fibrogenic factors [19]. Collagen types III and IV, FN, 
and laminin are present in both early and late 
idiopathic ERMs [14] (Table 4). 
Newly formed ERM collagens along with the density of 
the associated cells apparently enhance vitreoretinal 
adhesion. Collagens types I, III and V enhance 
mechanical functions, are major constituents of skin, 
muscles, blood vessels and fibrotic scar tissues, and 
can affect the mechanical properties of ERM. 
However, collagens types I, III and V do not appear in 
the normal vitreoretinal interface. Recently formed 
collagens not only provide strong adhesion to various 
tissues, but also influence the rigidity and digestibility 
of ERM [44].   
 
Table 4: Different Collagen Types and Their Role in ERM 
Collagen Type Role 
Collagen type I Promotes the fibrotic process and contributes to the formation of the hard collagen scaffold, where the myofibroblast 
precursor cells, when anchored there, become more susceptible to fibrogenic factors [19]. Also, it affects the mechanical 
properties of ERM. Although it enhances adhesion to various tissues, recently formed collagens may influence the rigidity 
and digestibility of ERM. Important component of idiopathic ERM [18, 44]. 
Collagen type II Proliferation and migration. It binds to cellular membrane receptors, while it has a significant role in matrix remodeling, 
fibrosis mediation and cell signaling. Important component of idiopathic ERM [18, 44]. 
Collagen type III Promotes the fibrotic process and contributes to the formation of the hard collagen scaffold, where the myofibroblast 
precursor cells, when anchored there, become more susceptible to fibrogenic factors [19]. Also, it affects the mechanical 
properties of ERM. In addition to enhancing adhesion to various tissues, recently formed collagens may influence the 
rigidity and digestibility of ERM. Important component of idiopathic ERM [18, 44].  
Collagen type IV Promotes the fibrotic process and contributes to the formation of the hard collagen scaffold, where the myofibroblast 
precursor cells, when anchored there, become more susceptible to fibrogenic factors. Important component of idiopathic 
ERM [18, 19]. 
Collagen type V Affects the mechanical properties of ERM. In addition to enhancing adhesion to various tissues, recently formed collagens 
may influence the rigidity and digestibility of ERM. Important component of idiopathic ERM [18, 44].  
Collagen type VI Contribution to the proliferation, migration and fibroblasts to myofibroblasts transdifferentiation, a vital procedure for 
mediating fibrosis, scar contraction and matrix remodeling, in many fibrotic diseases including ERM. It also forms a fine 
fibrillar network in idiopathic ERM. Important component of idiopathic ERM [18, 44, 83-85]. 
Abbreviations: ERM: epiretinal membrane 
Changes of Cytokines and Growth Factors in ERM 
Formation 
Cytokines and growth factors are present in both idiopathic 
and secondary ERMs, and in VF. These peptide factors, 
which are mediators of angiogenesis, may cause or 
aggravate diabetic neovascularization and, given that the 
growth and contraction of the ERM are regulated by growth 
factors [39], they may be implicated in idiopathic and 
secondary ERMs progression [1, 35, 45, 46, 86, 87]. Also, 
intraocular cells secrete specific cytokines and growth 
factors during the formation of ERM [16].  
Cytokines contribute significantly to various inflammatory 
processes, to wound healing and fibrotic scarification. 
Fibrosis is associated with the activation of fibroblasts, 
which triggers collagen and glycosaminoglycan production. 
Release of soluble factors such as TGF-β and profibrotic 
mediators, like PDGF, IL-4, IL-6, IL-13 in the retina, triggers 
the fibrotic process via glial cells and macrophages [63, 64, 
88-91]. MGCs directly participate in the formation of 
idiopathic and secondary ERMs by promoting fibrotic 
changes within the eye [63, 90].  
Specific cytokines that participate in ERM formation and are 
specifically expressed in idiopathic ERMs include TGF-β [29, 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(2)  
98 A REVIEW OF LAST DECADE DEVELOPMENTS ON EPIRETINAL MEMBRANE PATHOGENESIS 
92], interleukin-6 (IL-6) [29, 57], VEGF [29, 57, 92], TNF-a 
[25, 29], connective tissue growth factor (CTGF) [29, 93] and 
CCL2 [25, 29]. In contrast, there are other T-cell cytokines 
and associated factors, such as IFNG, RORC, IL17A and 
TBX21, which have no correlation with ERM formation [47].  
In addition to cytokines, growth factors are expressed in 
idiopathic ERMs contributing to ERM pathogenesis. These 
factors include IL-6, TGF-β, nerve growth factor (NGF),  
CTGF, glial cell-line-derived growth factor (GDNF), PDGF, 
basic fibroblast growth factor (bFGF), pigment epithelium-
derived factor (PEDF) and VEGF, which promote the 
migration and/or proliferation of a heterogeneous variety of 
cells [9, 16, 29, 39, 94]. Other factors and receptors 
expressed in idiopathic and secondary (PDR or PVR) ERM 
include hepatocyte growth factor (HGF), monocyte 
chemoattractant protein-1 (MCP-1), NF-κB, activator 
protein-1 (AP-1), IL-8, TNF-a, angiopoietin-2 (ANGPT2) [43] 
and the receptors, neurotrophin receptor p75 (p75NTR), 
tyrosine kinase receptors (RTKs) trkA (Tropomyosin receptor 
kinase A), trkB (Tropomyosin receptor kinase B) and trkC 
(Tropomyosin receptor kinase C), which are involved in 
neurite growth [95].  
The Transforming Growth Factor-β Family 
The TGF-β family, in particular, has a crucial role in 
idiopathic and secondary ERM formation. It is involved in 
normal tissue repair and development of fibrosis. TGF-β 
members upregulate ECM production, inhibit protease 
synthesis and mediate both inflammatory response and 
myofibroblast differentiation, while retinal Müller cells and 
hyalocytes produce and activate TGF-β [18]. TGF-β 
members, in turn, regulate how Müller cells proliferate, 
migrate and transdifferentiate [18, 94]. However, 
involvement of transdifferentiated Müller cells in the 
synthesis of collagen in idiopathic ERM is not clarified. 
Specific profibrotic cytokines can induce retinal Müller cells 
to transdifferentiate into a myofibroblast-like phenotype, to 
produce a-SMA and trigger tissue contraction [18].  
Given that the ECM network including various collagen 
types, enhances the migration and proliferation of ERM 
cells, the TGF-β involvement in pathological ECM networks 
(that are responsible for idiopathic ERM) may explain its 
increase in the VF of patients with idiopathic ERM [94]. 
The TGF-β1 and TGF-β2 are upregulated in both the vitreous 
humor and the ERMs [18] which means that they play a 
significant role in idiopathic ERM pathogenesis. Expression 
of either TGF-β1 or TGF-β2 appears to be secondary in ERM, 
although there are indications that they may be involved in 
the origin of idiopathic ERM. TGF-β1 and NGF mRNA 
expression are enhanced in idiopathic ERM, while there may 
be differences in TGF-β1 and TGF-β2 levels within the 
vitreous. Indeed, the level of TGF-β2 seems to increase in 
the vitreous of eyes with idiopathic ERM, while the level of 
TGF-β1 does not increase. Previous studies of secondary 
(PDR and PVR) ERMs [9] indicated that TGF-β1 was the 
more relevant cytokine for ERM formation, detected in the 
vitreal humor of ERM patients and playing an essential role 
in fibroblast activities. However, the difference in TGF-β1 
and TGF-β2 levels within the vitreous indicates that 
contribution of TGF-β1 in the pathogenesis of idiopathic 
ERM  may be relatively insignificant. Moreover, presence of 
several activated cytokines characterizes the vitreal humor 
of ERM patients [63].  
TGF-β2 is, therefore, associated with development of 
idiopathic and secondary ERM and its levels are correlated 
with intraocular fibrosis [9, 15]. Moreover, age and cell 
signaling seem to be associated with production of TGF-β2 
in ERM [9]. The perceived prominence of TGF-𝛽2 as the 
most important growth factor in idiopathic ERM 
pathogenesis, which may stimulate the differentiation of 
glial cells or hyalocytes into myofibroblasts and trigger ERM 
contraction, makes TGF-β2 a significant therapeutic target 
to prevent idiopathic ERM formation and contraction [9, 
15]. Despite the fact, the underlying molecular mechanism 
is still not fully elucidated [94].  
Nerve Growth Factor 
NGF can also contribute to the myofibroblast 
differentiation. In addition, NGF receptors may have a 
crucial role in this process. Hence, NGF may support the 
development of idiopathic ERM via the fine tuning of bound 
versus free NGF levels. Both increased expression and 
utilization of NGF may be involved in intracellular and 
intercellular signals leading to ERM. Therefore, both TGF-β2 
and NGF contribute to idiopathic ERM pathogenesis, while 
NGF can induce functional changes in ERM cells and be a 
basis for evaluation of ERM pathology [9].    
Vascular Endothelial Growth Factor  
VEGF is an EC- mitogen and angiogenic inducer, which is 
greatly expressed in various retinal cell types in case of 
hypoxia [96]. It contributes to ocular cell growth and 
proliferation and is practically undetectable in the VF under 
physiological conditions [16]. VEGF is a vitreoretinal growth 
factor [15] that contributes to the formation of idiopathic 
ERM [96]. In fact, VEGF-A contributes to retinal 
neovascularization and secondary (PDR) ERM [97], while the 
VEGF-A gene is overexpressed in ERMs [15, 17]. VEGF is 
strongly interacting with alpha B-crystallin (CRYAB). Given 
that CRYAB binds to VEGF protein, it is suspected, but not 
confirmed, that CRYAB and VEGF are collectively involved in 
human diabetic retinopathy. In addition, recent reports 
indicate that CRYAB is upregulated in neovascularization 
during the formation of secondary (PDR) ERM [97]. 
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Insulin-like Growth Factor  
Insulin-like growth factor (IGF) apparently contributes to the 
progression of ERMs [9, 20, 23, 66], especially during PDR 
[20, 98]. The IGF system involved in the inflammation 
process [20, 45, 65] also stimulates ERM contraction [20, 
23].  
Furthermore, protein array analysis indicates that cytokines 
and growth factors in the aqueous fluid (AF) and VF of eyes 
with idiopathic ERM do not appear to differ significantly in 
their concentrations. Thus, only the homodimer form of 
PDGF-A is overexpressed in the VF compared to the AF [16]. 
The Platelet-Derived Growth Factor Receptor 
The PDGF receptor and its subunits have been investigated 
in patients with secondary (PVR) ERM, whereby the PDGFRa 
subunit is more frequently encountered than the PDGFR𝛽 
subunit [99-101]. PDGF binds to the PDGF receptor. It is an 
autocrine growth factor whose production is stimulated by 
RPE cell [99, 102]. During wound healing the interaction of 
PDGF with its receptor is enhanced, suggesting that PDGF 
may be another factor that contributes to ERM formation 
[99].      
After RPE cells migration to the ERM or the vitreous cavity, 
they undertake the role of secreting stimulatory factors 
[100]. RPE cells and glial cells are attracted by PDGF, which 
may also function as a mitogen for these cells [103-105]. 
PDGF also enhance recruitment of new cells along with the 
proliferation of ERM cells. In addition, PDGF and VEGF take 
part in ERM evolution, as VEGF is localized to several 
secondary ERM cells [99, 105]. 
Glial Cell-Line-Derived Growth Factor  
GDNF and its receptors seem to be involved in several 
proliferative vitreoretinal disorders, however, their role in 
ERM formation, especially idiopathic one, has not been 
widely studied. Given that GDNF levels are far below the 
sensitivity threshold in idiopathic ERM samples [15], there 
are serious doubts regarding the association of GDNF with 
idiopathic ERM [9].   
Neurotrophin Receptors 
Finally, expression of neurotrophin receptor mRNAs (trkA, 
trkB, trkC, and p75NTR) in idiopathic and secondary (PDR) 
ERMs are similar. However, NGF in idiopathic ERM is 
significantly higher. In contrast, GFR𝛼1 (GDNF family 
receptor alpha-1) receptor mRNA is higher in idiopathic 
ERMs compared to secondary (PDR) ERMs, while GFR𝛼2 
(GDNF family receptor alpha-2) expression levels are 
extremely increased in secondary (PDR) ERMs [95].  
Changes of Other Proteins Specific to Idiopathic ERM 
Given the anatomically close relationship between the 
vitreous and the retina [106], the pathological mechanism 
of retinal diseases is influenced by changes in the vitreous 
proteins. The study of the vitreous proteome is therefore 
crucial to understand idiopathic ERM and differential 
protein expression in the AF and VF of eyes affected by 
idiopathic ERMs. To this date, 323 proteins have been 
identified in the AF and VF of patients with idiopathic ERMs 
[29]. Of these, 12 are differentially expressed, in a significant 
manner in AF versus VF; however, 8 proteins are 
comparably overexpressed in VF versus AF, whereas 4 
proteins are similarly overexpressed in AF and VF. 
Fibrinogen A is the most highly expressed protein in the VF 
in ERM development, possibly due to local retinal 
inflammation caused by retinal breaks or RD. Thus, small 
blood vessels are dilated in this area, permitting the 
extravagation of soluble factors (including fibrinogen) into 
the VF. However, the rest of the proteins significantly 
overexpressed in the VF compared to the AF, or the four 
proteins overexpressed in the AF, are not thought to be 
important pathogenetic factors for idiopathic ERM [15, 16, 
29]. 
Other studies of idiopathic ERM vitreous proteome 
identified (without specifically mentioning all of them) 233 
proteins that are expressed at lower levels, including ESR1 
protein, and 179 proteins that are expressed at higher 
levels. The obvious conclusion that there are severe level 
changes in several proteins in patients with idiopathic ERMs 
was also accompanied by the finding that vitreous protein 
concentration is, on the average, significantly higher in 
idiopathic ERM [29]. In idiopathic ERMs there are several 
proteins including cytokines and growth factors that are less 
abundantly expressed in contrast to others (e.g., heavy and 
light chains of immunoglobulin G (IgG), transferrin (TF), a1-
antichymotrypsin (a1ACT), a2-HS-glycoprotein (AHSG), 
hemopexin (Hpx), a1- antitrypsin (A1A), serum albumin, 
antithrombin III (ATIII), transthyretin (TTR), apolipoprotein 
A-1 (Apo A-1), fibrinogen γ chain (FGG), apolipoprotein J 
(Apoj), haptoglobin-1 (Hp) and AP-1) that are more 
abundantly expressed [15, 39, 107]. It is interesting that 
these proteins are also common in macular holes (MHs), 
indicating that ERMs and MHs follow similar inflammatory 
processes [15]. Interestingly, matrix metalloproteinase and 
plasminogen are present in the idiopathic ERM vitreous 
proteome, while lower levels are detected for most 
cytoskeleton proteins, indicating that there are severe 
proteins changes in idiopathic ERM process [29].  
The UBE2O (Ubiquitin-conjugating enzyme E2 O) protein is 
upregulated in the idiopathic ERM proteome and the 
vitreous. Ubiquitination is a significant enzymatic post-
translational modification of all eukaryotic organisms. Post-
translational modification of proteins by ubiquitin (Ub) 
determines several functions including DNA repair, 
procedures of endocytosis and cellular signaling and control 
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of protein quality. Idiopathic ERM pathogenesis is 
associated with protein misfolding and subsequent 
aggregation. These procedures influence negatively proteins 
while they also decrease production of new proteins. 
However, validation of UBE2O as a protein biomarker of 
idiopathic ERMs needs to be evaluated on larger samples 
[29]. 
A long part of LR11 (11 ligand-binding repeats, also known 
as SorLA or SORL1) is thought to play a key role in the 
pathogenesis of idiopathic ERM and its VF levels of eyes 
with idiopathic ERM, especially of the proliferative subtype, 
are apparently upregulated. LR11 is considered a risk factor 
for the progression of idiopathic ERM given that it provokes 
migration and proliferation of several cells, and as its 
possible association with the TGF-β2 signals. LR11 is thought 
to act independent from clinical characteristics such as age, 
hypertension and diabetes mellitus [94]. 
Finally, removed idiopathic ERM specimens were 
immunostain positive for GFAP, vimentin, CD45, CD68, 
CD163 and cellular retinaldehyde binding protein (CRALBP), 
which indicates the role of hyalocytes and glial cells [15]. 
GFAP, in particular, is elevated in both idiopathic and 
secondary (PDR) ERM formation [22].  
Changes of Proteins That Occur in Both Idiopathic and 
Secondary ERMs 
Apart from proteins specific to idiopathic ERM, there is a 
great variety of proteins involved in both idiopathic and 
secondary ERMs. Proteins like FN, laminin and VTN promote 
cell adhesion and contribute to idiopathic and secondary 
(PDR) ERM formation. FN, in particular, is a multifunctional 
glycoprotein that its association with ERM was described 
more than 10 years ago [6]. It promotes cell-to-cell and cell–
to-substrate adhesion and is thought to be one of the 
earliest factors involved in wound healing. It is also involved 
in the formation of transmembrane links between different 
cells and of temporary scaffolds, thus providing structural 
integrity and contraction. FN is also a key participant in cell 
differentiation, migration and proliferation of fibroblasts 
and ECs, events that are characteristic of ERM formation [6, 
84]. 
A gene with 50 exons encodes FN mRNA. It codes extra 
domains A (EDA) and B (EDB), and type III homology 
connecting segment (IIICS), each identified by alternative 
splicing. Differential pre-mRNA processing potentially leads 
to 21 different FN isoforms. The EDB FN variant, in 
particular, is highly expressed in proliferating tissues (e.g., in 
embryos or tumors), but is not detected in normal adult 
tissues, the main reason it has been proposed as an 
angiogenic marker [6]. 
Ιn both idiopathic and secondary (PDR) ERMs, collagen type 
IV, FN and EDBFN are some ECM proteins that are 
overexpressed. Their overexpression is associated with 
elevated TGF-β and endothelin-1 (ET-1), which is more 
pronounced in idiopathic ERMs [6].  
Neovascularization is considered as the first step in ERM 
formation. Neovascularization is a process where many 
angiogenic factors like apelin have a significant role [35, 45, 
46, 86, 87, 108]. Apelin is upregulated in secondary (PDR) 
ERMs, while there is increased apelin mRNA expression in 
secondary ERMs. Apelin signaling is an important 
contributor to the formation of adventitia and in 
angiogenesis. It triggers EC proliferation while, in vitro, it 
promotes migration and tube formation. Apelin, e.g., is 
upregulated during tumor neovascularization and thus is 
considered vital for embryonic vascular development. 
Interestingly, apelin is not co-expressed with FN, but is co-
expressed with glial-cell-specific, vascular EC and RPE cell 
markers. It is also involved in the differentiation of glial cells 
and vessels, whereas its expression is upregulated in the 
vascular system and vessel formation. Moreover, apelin and 
VEGF coordinate with each other in angiogenesis and gliosis, 
as they are co-expressed in secondary ERMs [35].  
Apelin is also present in the vascular and glial components 
of ERMs. Thus, elevated apelin expression is associated with 
a characteristic microenvironment around new vessels, 
triggered by glial cell proliferation. Furthermore, it 
upregulates expression of adhesion molecules and 
promotes cell aggregation independently of cell expansion 
[35]. 
The expression of SP1 in secondary (PDR) ERMs has not 
been determined. Nevertheless, the mRNA of SPI is highly 
expressed in secondary ERMs, while the SP1 protein is 
mainly colocalized with VEGF which is significant for ERM 
formation. SP1-like proteins bind to GC-rich motifs of many 
promoters and are involved in several cellular activities. The 
expression of various genes like TGF-β, VEGF fibrogenic 
factors and matrix genes is regulated by SP1, thus these 
cytokines may be detected in the VF and secondary ERMs. 
Moreover, SP1 may be crucial for overexpression of VEGF, 
given its central role in angiogenesis, cancer and ERM 
pathogenesis [79, 80, 109].  
ET with its 3 isoforms ET-1, ET-2, and ET-3. ET-1, is a potent 
vasoconstrictor molecule involved in several types of ERM. 
ET is recognized by ET receptors A (ETA) and B (ETB) [22]. 
ET-1 is a peptide produced by EC that triggers 
vasoconstriction when it interacts with ETA on the VSMC. It 
also stimulates mitogenic action on VSMC. ET-1 gene 
expression in EC is induced by low levels of tissue oxygen, 
synthesized by human RPE cells and expressed in retinal, 
neural, glial and vascular cells and in the optic nerve, while a 
breakdown of the blood-retinal barrier is suspected to 
increase its release [105].  
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Little is known about the ET-1 expression and its association 
to fibroblast proliferation in secondary, especially PDR, 
ERMs. There are reports about its essential role in mediating 
fibrosis in secondary ERMs, although it is not clear if the 
membrane cells produce ET-1 [22, 110-112].   
Nonetheless, glial cells secrete ET-1 in idiopathic as well 
as secondary (PVR) ERMs, whereas RPE cells secrete ET-1 
only in secondary (PVR) ERMs. Therefore, ET-1 may play 
a central role in formation and contraction of PVR ERMs, 
given that glial and RPE cells contribute to this process. In 
addition, ETA and ETB are detected in both idiopathic 
and secondary (PVR) ERMs [105], while ET-1 expression is 
elevated in secondary (PDR) ERMs. However, the role 
and expression of ET-1 and ETB in secondary (PDR) ERMs 
remains unclear compared to idiopathic ERMs [22, 105].  
ET-1 and S100A4 are possibly upregulated in PDR ERMs, 
while staining techniques show that ET-1 and S100A4 are 
colocalized. This indicates an association between ET-1 
and fibroblastic proliferation. In addition, it indicates that 
idiopathic and secondary ERMs are mediated by different 
mechanisms, especially as ET-1 seems to be a crucial 
factor in advanced PDR and fibroblastic transition. 
Therefore, ET potentially contributes to idiopathic and 
secondary ERM [22]. 
Epithelial membrane protein-2 (EMP2) is significantly 
expressed in many intraocular membranes. This suggests 
that RPE-derived cells are a crucial or predominant cell 
type in idiopathic and secondary (PVR) ERMs, given that 
EMP2 is a regulator of integrins, and is highly expressed 
in the RPE. EMP2 is also expressed in many secondary 
(PVR) ERMs, but additional research is needed to 
establish the association between EMP2 and secondary 
ERM [113]. Older studies indicated that ECM components 
like FN, VTN and laminin were also significant 
components of secondary (PVR) ERMs, which were 
detected in vitreous [29]. 
Another protein expressed in ERM is aquaporin (AQP). 
AQP1 has been described to be active in several cell 
types of the retina during both pathological and non-
pathological conditions [114-119]. AQPs are integral 
transmembrane water channels and implicated in 
migration and proliferation during idiopathic and 
secondary (PVR) ERM formation [114, 120-127]. Indeed, 
AQP1 is detected at both the protein and mRNA levels, 
especially at the edges of membranes from idiopathic 
and secondary (PVR) ERMs [114].  
ANP (Atrial natriuretic peptide) also has a crucial role for 
ERM formation. The ANP protein, is a natural inhibitor of 
angiogenesis. ANP possibly regulates the growth of 
secondary (PVR) ERMs and is expressed by several cells 
of ERM tissue, including vascular EC, RPE cells, glial cells, 
macrophages, vascular smooth muscle cells (VSMC) and 
fibroblasts. Thus, most cells that contribute to ERM 
formation express ANP. Because ANP is implicated in 
increased glial proliferation, it might contribute to 
secondary (PDR) ERMs formation [96, 128].   
Periostin (POSTN) is another protein that plays a 
significant role mainly in secondary (PVR) ERMs. Periostin 
mRNA is detected in secondary ERMs, while it is low in 
normal retinas. It interacts with integrins αvβ1, αvβ3 and 
αvβ5 under conditions of tissue development and 
remodeling and thus enhances cell motility. POSTN is 
also implicated with development of several tissues and 
organs, including teeth, heart valves, bone and in tumor 
metastasis [17].   
Periostin is found in pathologically fibrotic areas, and it 
may be essential for the development of PDR-ERM. It is 
suggested that periostin is significantly increased in the 
vitreous of eyes with secondary ERMs, which indicates its 
association with proliferation of secondary ERMs [17].  
Finally, Snail protein may have a role in secondary (PVR) 
ERMs. Snail protein is primarily expressed in the nucleus 
and is detected via immunofluorescent staining. Several 
signaling pathways are involved in its regulation. Factors 
like Glycogen synthase kinase-3b (GSK-3b), 
Phosphatidylinositol 3-kinase (PI3K), Ras, Smad and MAP 
kinase enhance Snail regulation by TGF-β1. The 
expression of Snail in secondary (PVR) ERMs implicates 
its role in PVR pathogenesis. Moreover, Snail 
transcription factor has a significant role in epithelial to 
mesenchymal transition in human RPE cells, induced by 
TGF-β1, indicating that this protein may regulate the 
formation of secondary (PVR) ERMs [129] (Table 5).  
Inflammation Molecules in Idiopathic and Secondary 
ERM  
As already mentioned, idiopathic ERM pathophysiology 
involves a large number of inflammation proteins, 
immune reactions and cytoskeleton remolding. 
Therefore, classical, alternative and lectin-induced 
pathways of complement activation, have all significant 
roles in the idiopathic ERM process. Five proteins 
including C4A (Complement C4-A), C3 (Complement C3) 
and complement factor B (CFB), are increased in 
idiopathic ERM with C4A being significantly upregulated. 
In addition, inflammation occurring in idiopathic ERMs 
may implicate the complement and coagulation cascade 
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Table 5. Proteins (Interleukins, Trophic and Transcription Factors) Involved in ERM Pathogenesis 
Protein (Abbreviation) Protein Type of ERM Influenced 
A1A a1- antitrypsin Idiopathic ERM [15, 39, 100] 
a1ACT a1-antichymotrypsin Idiopathic ERM [15, 39, 100] 
AHSG a2-HS-glycoprotein Idiopathic ERM [15, 39, 100] 
ANGPT2 Angiopoietin-2 Idiopathic and secondary (PDR or PVR) ERM [43] 
ANP Atrial natriuretic peptide  Secondary (PVR) ERM [64] 
AP-1 Activator protein-1 Idiopathic and secondary (PDR or PVR) ERM [43] 
Apo A-1 Apolipoprotein A-1 Idiopathic ERM [15, 39, 100] 
Apoj Apolipoprotein J Idiopathic ERM [15, 39, 100] 
AQP1 Aquaporin-1 Idiopathic and secondary (PVR) ERM [103] 
ATIII Antithrombin III Idiopathic ERM [15, 39, 100] 
bFGF Basic fibroblast growth factor  Idiopathic and secondary (PDR or PVR) ERM [15, 91] 
C3 Complement C3 Idiopathic ERM [29] 
C4A Complement C4-A Idiopathic ERM [29] 
CCL2 Chemokine (C-C motif) ligand 2 Idiopathic ERM [29] 
CCL26 Chemokine (C-C motif) ligand 26 ERM formation [63] 
CCL27 Chemokine (C-C motif) ligand 27 ERM formation [63] 
CFB Complement factor B Idiopathic ERM [29] 
CRYAB Alpha B crystallin Secondary (PDR) ERM [92] 
CTGF Connective tissue growth factor Idiopathic ERM [29, 89] 
CXCL6 Chemokine (C-X-C motif) ligand 6 ERM formation [63] 
CXCL10 Chemokine (C-X-C motif) ligand 10 ERM formation [63] 
CXCL11 Chemokine (C-X-C motif) ligand 11 ERM formation [63] 
EMP2 Epithelial membrane protein-2  Idiopathic and secondary (PVR) ERM [29] 
ET Endothelin Idiopathic and secondary (PDR) ERM [6] 
HGF Hepatocyte growth factor  Idiopathic and secondary (PDR or PVR) ERM [43] 
Hp Haptoglobin-1 Idiopathic ERM [15, 39, 100]  
FGG Fibrinogen γ chain Idiopathic ERM [15, 39, 100] 
FN Fibronectin Idiopathic and secondary (PDR) ERM [6] 
GDNF Glial cell line derived growth factor  Idiopathic [9, 15] and secondary (PDR or PVR) ERM [91] 
GFAP Glial fibrillary acidic protein Idiopathic and secondary (PDR) ERM [22] 
GFR𝛼1 GDNF family receptor alpha-1 Idiopathic ERMs [91] 
GFR𝛼2 GDNF family receptor alpha-2 Secondary (PDR) ERM [91] 
Hpx Hemopexin Idiopathic ERM [15, 39, 100] 
ICAM-1 Intracellular adhesion molecule 1  Idiopathic ERM and secondary ERMs [16] 
IGF Insulin-like growth factor  Secondary (PDR) ERM [20, 46] 
IgG Immunoglobulin G Idiopathic ERM [15, 39, 100] 
IL-1b Interleukin-1b Idiopathic and secondary ERM [63] 
IL-2 Interleukin-2 Idiopathic and secondary ERM [63] 
IL-4 Interleukin-4 Idiopathic and secondary ERM [63] 
IL-6 Interleukin-6 Idiopathic and secondary ERM [63] 
IL-8 Interleukin-8 Idiopathic and secondary (PDR or PVR) ERM [43] 
IL-10 Interleukin-10 Idiopathic and secondary ERM [63] 
IL-13 Interleukin-13 Idiopathic and secondary ERM [63] 
MCP-1 Monocyte chemoattractant protein-1  Idiopathic and secondary (PDR or PVR) ERM [43] 
NF-κB Nuclear factor kappa-B Idiopathic ERMs [50, 51] 
NGF Nerve growth factor Idiopathic [9, 29] and secondary (PDR or PVR) ERM [91] 
p75NTR p75 neurotrophin receptor Idiopathic and secondary (PDR or PVR) ERM [91] 
PDGF Platelet-derived growth factor Idiopathic [9] and secondary ERM [65] 
PDGF-A Platelet-derived growth factor A  Idiopathic ERM [16] 
PEDF Pigment epithelium-derived factor  Idiopathic ERM [29] 
POSTN Periostin Secondary (PVR) ERM [17] 
SP1 Specificity protein 1 Secondary (PDR) ERM [79] 
TF Transferrin Idiopathic ERM [15, 39, 100] 
TGF-β Transforming growth factor-β Idiopathic and secondary ERM [18] 
TGF-β1 Transforming growth factor-β1 Secondary (PDR and PVR) ERM [9, 18] 
TGF-β2 Transforming growth factor-β2 idiopathic and secondary ERM [9, 15, 18] 
TNF-a  Tumor necrosis factor alpha Idiopathic and secondary ERM [63] 
TrkA Tropomyosin receptor kinase A Idiopathic and secondary (PDR or PVR) ERM [91] 
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TrkB Tropomyosin receptor kinase B Idiopathic and secondary (PDR or PVR) ERM [91] 
TrkC Tropomyosin receptor kinase C Idiopathic and secondary (PDR or PVR) ERM [91] 
TTR Transthyretin Idiopathic ERM [15, 39, 100] 
VEGF Vascular endothelial growth factor Idiopathic ERM [64] 
VEGF-A Vascular endothelial growth factor-A Secondary (PDR) ERM [92] 
VTN Vitronectin Idiopathic and secondary (PDR) ERM [6] 
UBE2O Ubiquitin-conjugating enzyme E2 O Idiopathic ERM [29] 
Abbreviations: ERM: epiretinal membrane; A1A: a1- antitrypsin; a1ACT: a1-antichymotrypsin; AHSG: a2-HS-glycoprotein; ANGPT2: Angiopoietin-2; PDR: 
proliferative diabetic retinopathy; PVR: proliferative vitreoretinopathy; ANP: Atrial natriuretic peptide; AP-1: Activator protein-1; Apo A-1: Apolipoprotein A-1; 
Apoj: Apolipoprotein J; AQP1: Aquaporin-1; ATIII: Antithrombin III; bFGF: Basic fibroblast growth factor; C3: Complement C3; C4A: Complement C4-A; CCL2: 
Chemokine (C-C motif) ligand 2; CCL26: Chemokine (C-C motif) ligand 26; CCL27: Chemokine (C-C motif) ligand 27; CFB: Complement factor B; CRYAB: Alpha B 
crystalline; CTGF: Connective tissue growth factor; CXCL6: Chemokine (C-X-C motif) ligand 6; CXCL10: Chemokine (C-X-C motif) ligand 10; CXCL11: Chemokine (C-
X-C motif) ligand 11;  EMP2: Epithelial membrane protein-2; ET: Endothelin; HGF: Hepatocyte growth factor; Hp: Haptoglobin-1; FGG: Fibrinogen γ chain; FN: 
Fibronectin; GDNF: Glial cell line΄derived growth factor; GFAP: Glial fibrillary acidic protein; GFRα1: GDNF family receptor alpha-1; GFRα2: GDNF family receptor 
alpha-2 Hpx: Hemopexin; ICAM-01: Intracellular adhesion molecule 1; IGF: Insulin-like growth factor; IgG: Immunoglobulin G; IL-1b: Interleukin-1b; IL-2: 
Interleukin-2; IL-4: Interleukin-4; IL-6: Interleukin-6; IL-8: Interleukin-8; IL-10: Interleukin-10; IL-13: Interleukin-13; MCP-1: Monocyte chemoattractant protein-1; 
NF-κB: Nuclear factor kappa-B; NGF: Nerve growth factor; p75NTR: p75 neurotrophin receptor; PDGF: Platelet-derived growth factor; PDGF-A: Platelet-derived 
growth factor-A; PEDF: Pigment epithelium-derived factor; POSTN: Periostin; SP1: Specificity protein 1; TF: Transferrin; TGF-β: Transforming growth factor-β; TGF-
β1: Transforming growth factor-β1; TGF-β2: Transforming growth factor-β2; TNF-a: Tumor necrosis factor alpha; TrkA: Tropomyosin receptor kinase A; TrkB: 
Tropomyosin receptor kinase B; TrkC: Tropomyosin receptor kinase C; TTR: Transthyretin; VEGF: Vascular endothelial growth factor; VEGF-A: Vascular 
endothelial growth factor-A; VTN: Vitronectin; UBE20: Ubiquitin-conjugating enzyme E2 O 
Table 6. Abbreviations used in the text 
Expanded form Abbreviation 
a-Smooth Muscle Actin a-SMA 
Activator Protein-1  AP-1 
Aquaporin AQP 
Aqueous Fluids AF 
Atrial Natriuretic Peptide ANP 
basic Fibroblast Growth Factor  bFGF 
Chemokine C-X-C motif Ligand 1 CXCL1 
EndoThelin-1  ET-1 
EpiRetinal Membrane  ERM 
Epithelial Membrane Protein-2  EMP2 
ET receptors A  ETA 
ET receptors B  ETB 
Extra Domain A  EDA 
Extra Domain B  EDB 
Extracellular Matrix    ECM 
Fibronectin FN 
Glial cell-line-Derived Growth Factor  GDNF 
Glial Fibrillary Acidic Protein GFAP 
Glycogen Synthase Kinase-3b  GSK-3b 
Hepatocyte Growth Factor  HGF 
Immunoglobulin G  IgG 
Insulin-like Growth Factor IGF 
 Interleukin -6 IL-6 
 Interleukin -8  IL-8 
Internal Limiting Membrane ILM 
Intracellular Adhesion Molecule 1  ICAM-1  
11 Ligand-binding Repeats (also known as SorLA or SORL1) LR11 
Macular Holes  MHs 
Monocyte Chemoattractant Protein-1  MCP-1 
Müller Glial Cells MGCs 
Natriuretic Peptide NP 
Nerve Growth Factor  NGF 
Nuclear Factor Kappa B NF-κB 
Phosphatidylinositol 3-Kinase  PI3K 
Pigment Epithelium-Derived Factor  PEDF 
Platelet-Derived Growth Factor PDGF 
Platelet-Derived Growth Factor A  PDGF-A 
Posterior Vitreous Detachment   PVD 
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Preretinal Macular Fibrosis  PMF 
Proliferative Diabetic Retinopathy  PDR 
Proliferative  Vitreoretinopathy PVR 
Retinal Detachment RD 
Retinal Pigment Epithelium cells  RPE 
Tenascin C TNC 
Transforming Growth Factor TGF 
Transforming Growth Factor-β TGF-β 
Tropomyosin Receptor Kinase A TrkA 
Tropomyosin Receptor Kinase B TrkB 
Tropomyosin Receptor Kinase C TrkC 
Tumor Necrosis Factor alpha TNFα 
Type III homology Connecting Segment  IIICS 
Tyrosine Kinase Receptors  RTKs 
Ubiquitin  Ub 
v-REL avian reticuloendotheliosis viral oncogene homolog A RELA 
Vascular Endothelial Growth Factor VEGF 
Vascular Endothelial Growth Factor-A  VEGF-A 
Vascular Smooth Muscle Cells  VSMC 
Vitreous Fluids VF 
Wild-type p53-Induced Phosphatase 1  Wip1 
 
Cellular adhesion molecules also have an essential role 
for the binding of circulating inflammatory cells to 
specific sites, while they play a crucial role in cell 
proliferation. There are 25 cell adhesion proteins 
detected in AF and VF compartments of eyes affected by 
idiopathic ERM. The protein intracellular adhesion 
molecule 1 (ICAM-1) is detectable in the VF of eyes with 
idiopathic ERM, in contrast to AF from the same eyes, 
while it is frequently detected in the ECM of idiopathic 
ERM and in the endothelium of secondary ERMs [16]. 
Development of ERMs strongly correlates with the 
presence of CD44 and VCAM-1. CD44, a cell-surface 
glycoprotein, is involved in a wide variety of functions, 
including cell migration and adhesion, tumor growth and 
progression, also it is receptor for hyaluronic acid [17, 
130]. In addition, it is involved in epithelial to 
mesenchymal transition, which is induced by TNF-a. 
VCAM-1 interacts with VLA4 and might influence immune 
responses and leukocyte emigration to inflammation 
sites [17, 131]. The apparent coordinated upregulation of 
CD44 and VCAM-1 found in the vitreous of eyes with 
secondary ERMs indicate their significant involvement in 
the development of secondary (PVR) ERMs [17]. 
Finally, development of fibrotic and inflammatory 
processes is related to increased levels of IL-1b, IL-2, IL- 
4, IL-6, IL-10, TNF-a and INF-c [63, 89, 132-134]. Besides, 
presence of several proinflammatory chemokines and 
cytokines such as CCL26, CCL27, CXCL6, CXCL11 and INF-c 
that have a vital role in immunomodulation and 
inflammation, emphasizes the crucial role of 
inflammation in ERM formation [63, 135]. Table 6 
summarizes abbreviations used in the text. 
CONCLUSION 
As mentioned above, the main theories proposed for the 
pathogenesis of ERM, involve either cellular migration or 
cellular proliferation. The present mini review of the past 
decade developments tried to summarize, highlight and 
cross-correlate the major findings on the function of 
genes involved in ERM and their association with 
different types of cells, genes and gene expression 
products implicated in ERM formation.  
Although the issue of ERM pathogenesis remains poorly 
resolved, certain features of ERM are already apparent; 
1. With the exception of TGFb2 gene, there is apparently 
no overlap between the genes identified so far as being 
involved in idiopathic ERM, PVR-ERM and PDR-ERM 
(Table 3). This may imply that the pathogenesis of each 
of these forms of ERM may be different, but they may 
share similar pathways of expression as well. 
2. MGCs and fibroblasts or collagen cells are involved 
both in idiopathic ERM and PDR-ERM. However, based 
on our present knowledge, it is rather evident that in 
each case they use different sets of cytokines.  
3. The pathogenesis of secondary ERM (Tables 3,5) or its 
trigger(s) remains a terra incognita and an area of great 
research interest. 
4. Growth factors, cytokines and ECM have a central role 
in ERM pathogenesis , as they are implicated in several 
functions, including cellular signal transmission and 
tissue modification [9]. 
Finally, the great number of genes involved in ERM 
should serve as a warning for reaching premature 
conclusions regarding our expectations for potential 
gene manipulation-based treatments of ERM. The 
experience, so far, from the field of oncology argues 
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excessive reliance on genetic data for combating cancer 
[136-138].  Perhaps a similar argument can be made 
about ERM pathogenesis. Still, similar expectations can 
be raised about potential contributions of genetics-based 
therapies for its treatment. 
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